Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer

Status Withdrawn

Clinical Trial Summary

This clinical trial studies tivozanib before surgery in treating patients with localized kidney cancer. Tivozanib may stop the growth of tumor cells by blocking some of the growth factors needed for cell growth.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To assess the feasibility of conducting a trial of tivozanib in the neoadjuvant setting of localized (completely resectable) renal cell cancer (RCC). SECONDARY OBJECTIVES: I. To evaluate the safety of tivozanib in the neoadjuvant setting. II. To compare the tissue before and after tivozanib for pharmacodynamic purposes (tumor infiltrating lymphocytes, myeloid derived suppressor cells, necrosis in the primary tumor after exposure to tivozanib). III. To assess the overall response rate of tivozanib in primary tumors and correlate the radiographic changes, if any, to histo-pathological changes in the pathology specimen post-nephrectomy. IV. To compare the various growth factors (vascular endothelial growth factor [VEGF], interleukin-8 [IL-8], placenta growth factor [P1GF]) at baseline and post treatment. V. To assess the nephrectomy rate after applying neoadjuvant tivozanib in this primarily resectable RCC population. OUTLINE: Patients receive tivozanib orally (PO) once daily (QD) on days 1-21. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. 25 days after completion of tivozanib, patients undergo curative nephrectomy. After completion of study treatment, patients are followed up at 30 days. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01769885
Study type	Interventional
Source	Roswell Park Cancer Institute
Contact
Status	Withdrawn
Phase	N/A
Start date	March 14, 2013
Completion date	December 2, 2013

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02664883` - Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
Completed	`NCT00101114` - Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer	Phase 2
Completed	`NCT03229278` - Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma	Phase 1
Completed	`NCT01846520` - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers	N/A
Completed	`NCT01243359` - Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies	Phase 1
Terminated	`NCT00098618` - Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer	Phase 2
Terminated	`NCT02273752` - Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer	Phase 2
Completed	`NCT00005799` - Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	N/A
Completed	`NCT00499135` - Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors	Phase 1
Completed	`NCT01131234` - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00354250` - Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer	Phase 2
Completed	`NCT00060307` - Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer	Phase 2
Recruiting	`NCT03630692` - Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs
Completed	`NCT01548482` - Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Phase 1
Terminated	`NCT01582009` - Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate	Phase 1/Phase 2
Terminated	`NCT00324740` - Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer	Phase 1/Phase 2
Completed	`NCT01158521` - Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer	Phase 2
Completed	`NCT01155258` - Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors	Phase 1
Terminated	`NCT00684996` - Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer	Phase 1/Phase 2
Completed	`NCT00335556` - Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors	Phase 2